IceCure Medical highlighted a newly published peer-reviewed journal article demonstrating key clinical advantages of its ProSense cryoablation over radiofrequency ablation for early-stage breast cancer. The article, published in the International Journal of Surgery, which is ranked third globally among surgical journals, was authored by leading Japanese breast cancer specialists and reports that thermal ablation technologies have shown local tumor control rates comparable to breast-conserving surgery for appropriately selected patients with small breast tumors, while offering shorter procedures, minimal scarring, and improved cosmetic outcomes. The publication notes that cryoablation can be performed under local anesthesia, unlike radiofrequency ablation which requires general anesthesia, and allows flexible adjustment of the ice ball size with visible margins, whereas radiofrequency ablation is harder to control. IceCure is preparing for the 34th Annual Meeting of the Japanese Breast Cancer Society in Kyoto on June 25-27, 2026, and its exclusive distributor in Japan, Terumo Corporation, one of the world's top 20 medical device companies, is expected to submit ProSense for regulatory approval in breast cancer to Japan's Pharmaceuticals and Medical Devices Agency in the second half of 2026.
Icecure MedicalHighlighted study shows ProSense cryoablation advantages over radiofrequency ablation for early-stage breast cancer.
Terumo CorporationTerumo, as exclusive distributor in Japan, is expected to submit ProSense for regulatory approval, potentially boosting its medical device sales.